[1] L. S. Jones, B. Yazzie, and C. R. Middaugh, “Polyanions and the Proteome,”
Mol. Cell. Proteomics, vol. 3, no. 8, pp. 746–769, 2004, doi:
10.1074/mcp.r400008-mcp200.
[2] R. Srinivas, S. Samanta, and A. Chaudhuri, “Cationic amphiphiles: promising carriers of genetic materials in gene therapy,”
Chem. Soc. Rev., vol. 38, no. 12, p. 3326, 2009, doi:
10.1039/b813869a.
[3] S. M. Bromfield, E. Wilde, and D. K. Smith, “Heparin sensing and binding – taking supramolecular chemistry towards clinical applications,”
Chem. Soc. Rev., vol. 42, no. 23, p. 9184, 2013, doi:
10.1039/c3cs60278h.
[4] T. Sörensen, S. Leeb, J. Danielsson, and M. Oliveberg, “Polyanions Cause Protein Destabilization Similar to That in Live Cells,”
Biochemistry, vol. 60, no. 10, pp. 735–746, 2021, doi:
10.1021/acs.biochem.0c00889.
[5] “Chapter 4 Negatively Charged Polymers (Polyanions),” in
Developments in Soil Science, vol. 9, pp. 95–108, 1979, doi:
10.1016/s0166-2481(08)70115-6.
[6] E. Oduah, R. Linhardt, and S. Sharfstein, “Heparin: Past, Present, and Future,”
Pharmaceuticals, vol. 9, no. 3, p. 38, 2016, doi:
10.3390/ph9030038.
[7] D. Marson, E. Laurini, S. Aulic, M. Fermeglia, and S. Pricl, “Unchain My Blood: Lessons Learned from Self-Assembled Dendrimers as Nanoscale Heparin Binders,”
Biomolecules, vol. 9, no. 8, p. 385, 2019, doi:
10.3390/biom9080385.
[8] R. J. Linhardt, “Heparin and anticoagulation,”
Front. Biosci., vol. 21, no. 7, pp. 1372–1392, 2016, doi:
10.2741/4462.
[9] D. Mukherjee and E. J. Topol, “The role of low-molecular–weight heparin in cardiovascular diseases,”
Prog. Cardiovasc. Dis., vol. 45, no. 2, pp. 139–156, 2002, doi:
10.1053/pcad.2002.127679.
[10] S. Aslani
et al., “The applications of heparin in vascular tissue engineering,”
Microvasc. Res., vol. 131, p. 104027, 2020, doi: 10.1016/j.mvr.2020.104027.
[11] P. Wang
et al., “Heparin: An old drug for new clinical applications,”
Carbohydr. Polym., vol. 295, p. 119818, 2022, doi:
10.1016/j.carbpol.2022.119818.
[12] C. Bal dit Sollier, J.-G. Dillinger, and L. Drouet, “Anticoagulant activity and pleiotropic effects of heparin,”
J. Med. Vasc., vol. 45, no. 3, pp. 147–157, 2020, doi:
10.1016/j.jdmv.2020.03.002.
[13] P. Zhou, J.-X. Yin, H.-L. Tao, and H. Zhang, “Pathogenesis and management of heparin-induced thrombocytopenia and thrombosis,”
Clin. Chim. Acta, vol. 504, pp. 73–80, 2020, doi:
10.1016/j.cca.2020.02.002.
[14] L. Litov
et al., “Molecular Mechanism of the Anti-Inflammatory Action of Heparin,”
Int. J. Mol. Sci., vol. 22, no. 19, p. 10730, 2021, doi:
10.3390/ijms221910730.
[15] A. Vitiello and F. Ferrara, “Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update,”
Cardiovasc. Drugs Ther., vol. 37, no. 2, pp. 277–281, 2021, doi:
10.1007/s10557-021-07251-6.
[16] M.-T. Seffer, D. Cottam, L. G. Forni, and J. T. Kielstein, “Heparin 2.0: A New Approach to the Infection Crisis,”
Blood Purif., vol. 50, no. 1, pp. 28–34, 2020, doi:
10.1159/000508647.
[17] L. Li, X. Tian, G. Feng, and B. Chen, “The predictive value of heparin-binding protein for bacterial infections in patients with severe polytrauma,”
PLoS ONE, vol. 19, no. 12, p. e0300692, 2024, doi:
10.1371/journal.pone.0300692.
[18] J. Thachil, “The versatile heparin in COVID‐19,”
J. Thromb. Haemost., vol. 18, no. 5, pp. 1020–1022, 2020, doi:
10.1111/jth.14821.
[19] L. Mazilu
et al., “Thrombosis and Haemostasis challenges in COVID-19 – Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions—a mini review,”
Food Chem. Toxicol., vol. 148, p. 111974, 2021, doi:
10.1016/j.fct.2021.111974.
[20] H. N. Magnani, “Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection,”
Clin. Appl. Thromb. Hemost., vol. 27, 2021, doi:
10.1177/1076029620977702.
[21] J. Hogwood, E. Gray, and B. Mulloy, “Heparin, Heparan Sulphate and Sepsis: Potential New Options for Treatment,”
Pharmaceuticals, vol. 16, no. 2, p. 271, 2023, doi:
10.3390/ph16020271.
[22] S. Dey
et al., “DNA origami,”
Nat. Rev. Methods Primers, vol. 1, no. 1, 2021, doi:
10.1038/s43586-020-00009-8.
[23] S. Dastorani and R. Hasanzadeh Ghasemi, “Modeling and investigating the behavior of triangular origami DNA under the influence of laboratory temperature,”
Sci. Technol. Mech. Eng., vol. 1, no. 1, pp. 58–69, 2023. doi: 10.22034/stme.2022.162701 (in Persian).
[24] S. Dastorani, R. H. Ghasemi, and R. Soheilifard, “A Study on the Bending Stiffness of a New DNA Origami Nano-Joint,”
Mol. Biotechnol., vol. 63, no. 11, pp. 1057–1067, 2021, doi:
10.1007/s12033-021-00367-y.
[25] S. Dastorani
et al., “Modelling and structural investigation of a new DNA Origami based flexible bio-nano joint,”
Mol. Simul., vol. 46, no. 13, pp. 994–1003, 2020, doi:
10.1080/08927022.2020.1797019.
[26] S. Dastorani, M. Shariati, and R. Hasanzadeh Ghasemi, “Comparison of the bending behavior of DNA origami Nano beam using the nonlinear theory method and steered molecular dynamics simulation,”
Nano World, vol. 19, no. 73, pp. 45–54, 2024 (in Persian)
[45] K. A. Thornalley, E. Laurini, S. Pricl, and D. K. Smith, "Enantiomeric and Diastereomeric Self‐Assembled Multivalent Nanostructures: Understanding the Effects of Chirality on Binding to Polyanionic Heparin and DNA," Angewandte Chemie International Edition, vol. 57, no. 28, pp. 8530–8534, 2018. [Online]. Available: https://doi.org/10.1002/anie.201802741